Clinical Trial

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Name: To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis — clinical trial record (NCT07629583)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Trial Details

NCT Number	NCT07629583
Lead Sponsor	Genentech, Inc.
Conditions	Lupus Erythematosus, Systemic
Enrollment	46 participants
Start Date	2026-07-31
Primary Completion	2030-03-29 (estimated)
Study Completion	2030-03-29 (estimated)
Updated on ClinicalTrials.gov	2026-06-05